etomoxir has been researched along with lonidamine in 1 studies
| Studies (etomoxir) | Trials (etomoxir) | Recent Studies (post-2010) (etomoxir) | Studies (lonidamine) | Trials (lonidamine) | Recent Studies (post-2010) (lonidamine) |
|---|---|---|---|---|---|
| 260 | 8 | 93 | 402 | 55 | 97 |
| Protein | Taxonomy | etomoxir (IC50) | lonidamine (IC50) |
|---|---|---|---|
| M17 leucyl aminopeptidase | Plasmodium falciparum 3D7 | 7.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aller, P; Boyano-Adánez, Mdel C; Calviño, E; Calvo, S; de Blas, E; Estañ, MC; Guillén-Guío, B; Rial, E | 1 |
1 other study(ies) available for etomoxir and lonidamine
| Article | Year |
|---|---|
Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Deoxyglucose; Epoxy Compounds; Glycolysis; Humans; Indazoles; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides; Protein Kinases | 2014 |